{"entity":{"id":"qing-zhou","kind":"person","name":"Qing Zhou","aka":[],"tldr":"Chinese thoracic oncologist behind HARMONi-2, where the PD-1/VEGF bispecific ivonescimab beat pembrolizumab head to head.","summary":"Qing Zhou led HARMONi-2, the first randomised trial in which a new agent (ivonescimab, a PD-1 and VEGF bispecific antibody) beat pembrolizumab on progression-free survival in PD-L1-positive NSCLC, and HARMONi-A in EGFR-mutant disease after TKI failure. She works alongside Yi-Long Wu at the Guangdong Lung Cancer Institute and leads CTONG trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20Q%5BAuthor%5D%20ivonescimab"}],"tags":["lung","bispecific","china"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["bispecific-antibody"],"targets":["pd1","vegf"],"drugs":["ivonescimab","pembrolizumab"],"companies":[],"institutions":["guangdong-provincial-peoples-hospital","csco"],"pathways":[],"terms":[],"trials":["harmoni-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-harmoni-2-lancet-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital","institutionId":"guangdong-provincial-peoples-hospital","specialisms":["EGFR-mutant lung cancer","Bispecific antibodies","Immunotherapy","Chinese lung cancer trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20Q%5BAuthor%5D%20ivonescimab"}],"papers":[{"title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2)","journal":"Lancet","year":2025},{"title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant (HARMONi-A)","journal":"JAMA","year":2024,"doi":"10.1001/jama.2024.10613"},{"title":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","journal":"The Lancet","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HARMONi-2+ivonescimab+pembrolizumab+Lancet"}]},"route":"/people/qing-zhou/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/"},{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/"}],"trial":[{"id":"harmoni-2","kind":"trial","name":"HARMONi-2","route":"/trials/harmoni-2/"}],"paper":[{"id":"paper-harmoni-2-lancet-2025","kind":"paper","name":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","route":"/key-papers/paper-harmoni-2-lancet-2025/"}]}}